HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Successful treatment with imatinib mesylate of a CML patient in megakaryoblastic crisis with severe fibrosis.

Abstract
The prognosis of patients with chronic myeloid leukemia in blastic crisis (CML-BC) remains extremely poor, and multiagent chemotherapy regimens commonly used to treat acute leukemia offer only short-term benefits. Therefore, the advent of the novel molecularly targeted anticancer agent imatinib mesylate is a breakthrough in CML therapy. We present a CML patient in megakaryoblastic crisis with severe myelofibrosis, who was treated with imatinib at a dosage of 400 mg/day and achieved complete remission together with a marked regression of myelofibrosis after 1 month. The effect of imatinib on the long-term prognosis remains unclear, although the agent is clearly a promising drug for treating CML-BC even in cases of myelofibrosis.
AuthorsYuka Hirose, Hitoshi Kiyoi, Masanori Iwai, Toshiya Yokozawa, Masafumi Ito, Tomoki Naoe
JournalInternational journal of hematology (Int J Hematol) Vol. 76 Issue 4 Pg. 349-53 (Nov 2002) ISSN: 0925-5710 [Print] Japan
PMID12463599 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
Topics
  • Adult
  • Antineoplastic Agents (administration & dosage)
  • Benzamides
  • Blast Crisis (drug therapy)
  • Bone Marrow (pathology)
  • Female
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy, pathology)
  • Megakaryocytes (pathology)
  • Piperazines (administration & dosage)
  • Primary Myelofibrosis (drug therapy, etiology, pathology)
  • Pyrimidines (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: